GLYBURIDE AND METFORMIN HYDROCHLORIDE

N/A

Manufactured by Aurobindo Pharma Limited

579 FDA adverse event reports analyzed

Last updated: 2026-04-15

About GLYBURIDE AND METFORMIN HYDROCHLORIDE

GLYBURIDE AND METFORMIN HYDROCHLORIDE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Aurobindo Pharma Limited. The most commonly reported adverse reactions for GLYBURIDE AND METFORMIN HYDROCHLORIDE include BLOOD GLUCOSE INCREASED, HYPOGLYCAEMIA, DIARRHOEA, DRUG INEFFECTIVE, DYSPNOEA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for GLYBURIDE AND METFORMIN HYDROCHLORIDE.

Top Adverse Reactions

BLOOD GLUCOSE INCREASED21 reports
HYPOGLYCAEMIA20 reports
DIARRHOEA18 reports
DRUG INEFFECTIVE14 reports
DYSPNOEA13 reports
NAUSEA13 reports
RENAL FAILURE13 reports
PAIN12 reports
ASTHENIA11 reports
CARDIAC FAILURE CONGESTIVE11 reports
FLUSHING10 reports
RENAL IMPAIRMENT10 reports
DRUG INTERACTION9 reports
MYOCARDIAL INFARCTION9 reports
OEDEMA PERIPHERAL9 reports
ARTHRALGIA8 reports
BLOOD PRESSURE INCREASED7 reports
CONSTIPATION7 reports
CORONARY ARTERY DISEASE7 reports
FATIGUE7 reports
INJECTION SITE PAIN7 reports
MALAISE7 reports
PNEUMONIA7 reports
STRESS7 reports
ANXIETY6 reports
DIABETES MELLITUS6 reports
DRUG INTOLERANCE6 reports
GLYCOSYLATED HAEMOGLOBIN INCREASED6 reports
PAIN IN EXTREMITY6 reports
PARAESTHESIA6 reports
RHABDOMYOLYSIS6 reports
URINARY TRACT INFECTION6 reports
VOMITING6 reports
WEIGHT INCREASED6 reports
ANAEMIA5 reports
BACK PAIN5 reports
BLOOD GLUCOSE DECREASED5 reports
COMPLETED SUICIDE5 reports
DEHYDRATION5 reports
DIABETES MELLITUS INADEQUATE CONTROL5 reports
DIZZINESS5 reports
DRY MOUTH5 reports
EMOTIONAL DISTRESS5 reports
FEELING HOT5 reports
GENERAL PHYSICAL HEALTH DETERIORATION5 reports
HYPERGLYCAEMIA5 reports
HYPOTHYROIDISM5 reports
MYALGIA5 reports
OFF LABEL USE5 reports
OROPHARYNGEAL PAIN5 reports
PANCREATITIS5 reports
PRODUCT QUALITY ISSUE5 reports
PRURITUS5 reports
RENAL FAILURE ACUTE5 reports
UNEVALUABLE EVENT5 reports
ABDOMINAL PAIN4 reports
ADRENAL INSUFFICIENCY4 reports
ARTERIOSCLEROSIS4 reports
BALANCE DISORDER4 reports
BLOOD CREATININE INCREASED4 reports
BLOOD PRESSURE DECREASED4 reports
BLOOD TRIGLYCERIDES INCREASED4 reports
CONFUSIONAL STATE4 reports
GAIT DISTURBANCE4 reports
GRIP STRENGTH DECREASED4 reports
HYPERKALAEMIA4 reports
HYPERTENSION4 reports
HYPOKINESIA4 reports
INFECTION4 reports
INJECTION SITE BRUISING4 reports
INJURY4 reports
MYOCARDIAL ISCHAEMIA4 reports
PANCYTOPENIA4 reports
PERICARDITIS4 reports
THERAPEUTIC PRODUCT EFFECT INCOMPLETE4 reports
TOXICITY TO VARIOUS AGENTS4 reports
VISUAL IMPAIRMENT4 reports
ANHEDONIA3 reports
BLOOD CHOLESTEROL INCREASED3 reports
BLOOD POTASSIUM INCREASED3 reports
BURNING SENSATION3 reports
CARDIO RESPIRATORY ARREST3 reports
CEREBROVASCULAR ACCIDENT3 reports
CHEST PAIN3 reports
COLITIS3 reports
CONDITION AGGRAVATED3 reports
CONTUSION3 reports
COUGH3 reports
DEATH3 reports
DIABETIC NEUROPATHY3 reports
DYSPNOEA EXERTIONAL3 reports
ECONOMIC PROBLEM3 reports
ERYTHEMA3 reports
FALL3 reports
FEAR3 reports
FEBRILE NEUTROPENIA3 reports
GASTRIC DISORDER3 reports
GASTROINTESTINAL DISORDER3 reports
GASTROOESOPHAGEAL REFLUX DISEASE3 reports
HEADACHE3 reports

Report Outcomes

Out of 216 classified reports for GLYBURIDE AND METFORMIN HYDROCHLORIDE:

Serious 68.5%Non-Serious 31.5%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Female109 (51.7%)
Male102 (48.3%)

Reports by Age

Age 6012 reports
Age 619 reports
Age 586 reports
Age 666 reports
Age 756 reports
Age 595 reports
Age 635 reports
Age 655 reports
Age 675 reports
Age 684 reports
Age 694 reports
Age 774 reports
Age 914 reports
Age 443 reports
Age 473 reports
Age 503 reports
Age 523 reports
Age 623 reports
Age 643 reports
Age 723 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with GLYBURIDE AND METFORMIN HYDROCHLORIDE?

This profile reflects 579 FDA FAERS reports that mention GLYBURIDE AND METFORMIN HYDROCHLORIDE. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for GLYBURIDE AND METFORMIN HYDROCHLORIDE?

Frequently reported terms in FAERS include BLOOD GLUCOSE INCREASED, HYPOGLYCAEMIA, DIARRHOEA, DRUG INEFFECTIVE, DYSPNOEA, NAUSEA. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures GLYBURIDE AND METFORMIN HYDROCHLORIDE?

Labeling and FAERS entries often list Aurobindo Pharma Limited in connection with GLYBURIDE AND METFORMIN HYDROCHLORIDE. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.